Diagnostic methods for African horsesickness virus using monoclonal antibodies to structural and non-structural proteins

Ranz, Ana I.; Miguet, J. G.; Anaya, Carmen; Venteo, Ángel; Cortes, Elena; Vela, Carmen; Sanz, Antonio

doi:10.1016/0378-1135(92)90042-r

Cited by 16 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Basically, microtitre plates were coated with 1 lag/well of purified anti-VP2 MAb (8DF 1) or purified anti-VP5 MAb (10AE12) (Ranz et al, 1992) in PBS by overnight incubation at 4 °C. After five washes, plates were incubated with AcAHSV-4.2/5-infected cell extracts diluted 1/100 in PBS for 1 h at 37 °C, washed again and incubated with serial dilutions of horse sera for 1 h at 37 °C.…”

Section: Methodsmentioning

confidence: 99%

Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7

Diaz-Laviada

Roy

et al. 1996

Journal of General Virology

View full text Add to dashboard Cite

African horsesickness virus serotype 4 (AHSV-4) outer capsid protein VP2, or VP2 and VP5 plus inner capsid protein VP7, derived from single or dual recombinant baculovirus expression vectors were used in different combinations to immunize horses. When the proteins were purified by affinity chromatography, the combination of all three proteins induced low levels of neutralizing antibodies and conferred protection against virulent virus challenge. However, purified VP2 or VP2 and VP5 in the absence of VP7 failed to induce neutralizing antibodies and protection. Immunization with non-purified proteins enhanced the titres of neutralizing antibodies. Again, the combination of the three proteins was able to confer total protection to immunized horses, which showed absence of viraemia. The antigenicity of recombinant VP2 was analysed with a collection of 30 MAbs. Both purified and unpurified recombinant VP2 proteins showed different antigenic patterns in comparison to that of VP2 on virions. An immunization experiment with four more horses confirmed these results. The vaccine described here would not only prevent the disease, but would drastically reduce the propagation of the virus by vectors.

show abstract

Section: Methodsmentioning

confidence: 99%

Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7

Diaz-Laviada

Roy

et al. 1996

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…There are nine distinct serotypes of AHSV, which can be distinguished in virus or serum neutralisation tests (VNT or SNT). The identity of each serotype is controlled primarily by the amino acid sequence of VP2, which contains the majority of neutralising epitopes and is the principal serotype-specific antigen of AHSV [7], [8]. Animals that survive infection by a single AHSV serotype are subsequently protected against the homologous type, although they can still be infected by the other serotypes.…”

Section: Introductionmentioning

confidence: 99%

A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model

et al. 2011

View full text Add to dashboard Cite

African horse sickness (AHS) is a lethal viral disease of equids, which is transmitted by Culicoides midges that become infected after biting a viraemic host. The use of live attenuated vaccines has been vital for the control of this disease in endemic regions. However, there are safety concerns over their use in non-endemic countries. Research efforts over the last two decades have therefore focused on developing alternative vaccines based on recombinant baculovirus or live viral vectors expressing structural components of the AHS virion. However, ethical and financial considerations, relating to the use of infected horses in high biosecurity installations, have made progress very slow. We have therefore assessed the potential of an experimental mouse-model for AHSV infection for vaccine and immunology research. We initially characterised AHSV infection in this model, then tested the protective efficacy of a recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2).

show abstract

“…Annual vaccination is with polyvalent multiserotype mouse-brain or tissue culture grown live virus vaccine. Future vaccines may use AHSV surface VP2 protein as a subunit bio-tech vaccine [24] or VP2 plasmid as a DNA vaccine. The pathogenesis and epidemiology of AHS have similarities to infection of ruminants by another important veterinary Orbivirus namely bluetongue virus (see Sheep viruses below).…”

Section: African Horse Sicknessmentioning

confidence: 99%

Immunoprophylaxis against important virus diseases of horses, farm animals and birds

Patel¹,

Heldens²

2009

Vaccine

View full text Add to dashboard Cite

Since the refinement of tissue culture techniques for virus isolation and propagation from the mid 1960s onwards, veterinary virology has received much academic and industrial interest, and has now become a major global industry largely centred on vaccine development against economically important virus diseases of food animals. Bio-tech approaches have been widely used for improved vaccines development. While many viral diseases are controlled through vaccination, many still lack safe and efficacious vaccines. Additional challenges faced by academia, industry and governments are likely to come from viruses jumping species and also from the emergence of virulent variants of established viruses due to natural mutations. Also viral ecology is changing as the respective vectors adapt to new habitats as has been shown in the recent incursion by bluetongue virus into Europe. In this paper the current vaccines for livestock, horses and birds are described in a species by species order. The new promising bio-tech approaches using reverse genetics, non-replicating viral vectors, alpha virus vectors and genetic vaccines in conjunction with better adjuvants and better ways of vaccine delivery are discussed as well

show abstract

Diagnostic methods for African horsesickness virus using monoclonal antibodies to structural and non-structural proteins

Cited by 16 publications

References 14 publications

Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7

Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7

A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model

Immunoprophylaxis against important virus diseases of horses, farm animals and birds

Contact Info

Product

Resources

About